Seroprevalence of SARS-Cov-2 in the Setting of a Non-dedicated COVID-19 Hospital in a Low CoV-2 Incidence Area: Implications for Surgery

We have herein analysed the patients admitted to our Department that underwent serologic tests for SARS-CoV-2 either by Ab or RT PCR, to estimate the prevalence of COVID-19 in the setting of a non-dedicated COVID-19 hospital and in a low CoV-2 incidence area, and to evaluate if security measures are necessary for this context.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Covid19 COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections SARS (Severe Acute Respiratory Syndrome) Severe Acute Respiratory Syndrome Surgery Virus Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

AOU Cagliari

Cagliari, CA, 09100, Italy

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients hospitalized during pandemic spread

Exclusion criteria

Incomplete data

Treatment and study plan

SARS-CoV-2 Ab

Diagnostic Test

Patient test for specific antibodies for SARS-CoV-2

Primary outcomes

Seroprevalence of SARS-CoV-2

Time frame: 3 months

Positivity of specific IgM or IgG

Sponsors and collaborators

Lead sponsor

University of Cagliari

Other

Registry information

Important dates

Study start: 2020
Primary completion: 2020
Study completion: 2020
First posted: Jul 21, 2020
Registry last updated: Jul 21, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed